Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray

Programmed Death 1 Ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 IHC assays with various antibodies and cut-points have been used in clinical trials across tumor types. Comparative performance chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Morilla, Sandra, McGuire, John, Gaule, Patricia, Moore, Lauren, Acs, Balazs, Cougot, Delphine, Gown, Allen M., Yaziji, Hadi, Wang, Wei-Lien, Cartun, Richard W., Hornick, Jason L., Sholl, Lynette M., Qiu, Jingxin, Mino-Kenudson, Mari, Yi, Eunhee S., Beasley, Mary Beth, Merrick, Daniel T., Ambaye, Abiy B., Zhang, Zhong J., Walker, Jill, Rimm, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920558/
https://www.ncbi.nlm.nih.gov/pubmed/31409885
http://dx.doi.org/10.1038/s41374-019-0295-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920558/
https://www.ncbi.nlm.nih.gov/pubmed/31409885
http://dx.doi.org/10.1038/s41374-019-0295-9

Ejemplares similares